Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease

Karen C. Patterson, Beverly S. Franek, Joachim Müller-Quernheim, Anne I. Sperling, Nadera J. Sweiss, Timothy B. Niewold

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims: Sarcoidosis is a granulomatous disease of unknown etiology marked by tremendous clinical heterogeneity. Many patients enter remission with good long-term outcomes. Yet, chronic disease is not uncommon, and this important phenotype remains understudied. Identified alterations in local and circulating cytokines-specifically targeted for study, and often in the acute phase of disease-have informed our growing understanding of the immunopathogenesis of sarcoidosis. Our aim was to evaluate a broad panel of circulating cytokines in patients with chronic sarcoidosis. Among those with chronic disease, pulmonary fibrosis occurs in only a subset. To gain more insight into the determinants of the fibrotic response, we also determined if the phenotypes of fibrotic and non-fibrotic pulmonary sarcoidosis have distinct cytokine profiles. Results: In patients with sarcoidosis compared to controls, IL-5 was decreased, and IL-7 was increased. Both of these comparisons withstood rigorous statistical correction for multiple comparisons. GM-CSF met a nominal level of significance. We also detected an effect of phenotype, where IL-5 was significantly decreased in non-fibrotic compared to fibrotic pulmonary sarcoidosis, and compared to controls. Compared to controls, there was a trend towards a significant increase in IL-7 in fibrotic, but not in non-fibrotic pulmonary sarcoidosis. In contrast, compared to controls, there was a trend towards a significant increase in GM-CSF in non-fibrotic, but not in fibrotic pulmonary sarcoidosis. Conclusions: In a comprehensive evaluation of circulating cytokines in sarcoidosis, we found IL-5, IL-7, and GM-CSF to be altered. These findings provide a window into the immunopathogenesis of sarcoidosis. IL-7 is a novel sarcoidosis cytokine and, as a master regulator of lymphocytes, is an attractive target for further studies. By observing an effect of phenotype upon cytokine patterns, we also identify specific immune alterations which may contribute to clinical heterogeneity.

Original languageEnglish (US)
Pages (from-to)906-911
Number of pages6
JournalCytokine
Volume61
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Pulmonary diseases
Sarcoidosis
Lung Diseases
Interleukin-7
Pulmonary Sarcoidosis
Cytokines
Phenotype
Interleukin-5
Granulocyte-Macrophage Colony-Stimulating Factor
Chronic Disease
Lymphocytes
Pulmonary Fibrosis
Acute Disease

Keywords

  • Cytokines
  • Interleukin-5
  • Interleukin-7
  • Pulmonary fibrosis
  • Sarcoidosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Hematology
  • Biochemistry
  • Molecular Biology

Cite this

Patterson, K. C., Franek, B. S., Müller-Quernheim, J., Sperling, A. I., Sweiss, N. J., & Niewold, T. B. (2013). Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. Cytokine, 61(3), 906-911. https://doi.org/10.1016/j.cyto.2012.12.016

Circulating cytokines in sarcoidosis : Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. / Patterson, Karen C.; Franek, Beverly S.; Müller-Quernheim, Joachim; Sperling, Anne I.; Sweiss, Nadera J.; Niewold, Timothy B.

In: Cytokine, Vol. 61, No. 3, 03.2013, p. 906-911.

Research output: Contribution to journalArticle

Patterson, KC, Franek, BS, Müller-Quernheim, J, Sperling, AI, Sweiss, NJ & Niewold, TB 2013, 'Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease', Cytokine, vol. 61, no. 3, pp. 906-911. https://doi.org/10.1016/j.cyto.2012.12.016
Patterson, Karen C. ; Franek, Beverly S. ; Müller-Quernheim, Joachim ; Sperling, Anne I. ; Sweiss, Nadera J. ; Niewold, Timothy B. / Circulating cytokines in sarcoidosis : Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. In: Cytokine. 2013 ; Vol. 61, No. 3. pp. 906-911.
@article{1cab28db451d4369b2f9240e38b8c44b,
title = "Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease",
abstract = "Aims: Sarcoidosis is a granulomatous disease of unknown etiology marked by tremendous clinical heterogeneity. Many patients enter remission with good long-term outcomes. Yet, chronic disease is not uncommon, and this important phenotype remains understudied. Identified alterations in local and circulating cytokines-specifically targeted for study, and often in the acute phase of disease-have informed our growing understanding of the immunopathogenesis of sarcoidosis. Our aim was to evaluate a broad panel of circulating cytokines in patients with chronic sarcoidosis. Among those with chronic disease, pulmonary fibrosis occurs in only a subset. To gain more insight into the determinants of the fibrotic response, we also determined if the phenotypes of fibrotic and non-fibrotic pulmonary sarcoidosis have distinct cytokine profiles. Results: In patients with sarcoidosis compared to controls, IL-5 was decreased, and IL-7 was increased. Both of these comparisons withstood rigorous statistical correction for multiple comparisons. GM-CSF met a nominal level of significance. We also detected an effect of phenotype, where IL-5 was significantly decreased in non-fibrotic compared to fibrotic pulmonary sarcoidosis, and compared to controls. Compared to controls, there was a trend towards a significant increase in IL-7 in fibrotic, but not in non-fibrotic pulmonary sarcoidosis. In contrast, compared to controls, there was a trend towards a significant increase in GM-CSF in non-fibrotic, but not in fibrotic pulmonary sarcoidosis. Conclusions: In a comprehensive evaluation of circulating cytokines in sarcoidosis, we found IL-5, IL-7, and GM-CSF to be altered. These findings provide a window into the immunopathogenesis of sarcoidosis. IL-7 is a novel sarcoidosis cytokine and, as a master regulator of lymphocytes, is an attractive target for further studies. By observing an effect of phenotype upon cytokine patterns, we also identify specific immune alterations which may contribute to clinical heterogeneity.",
keywords = "Cytokines, Interleukin-5, Interleukin-7, Pulmonary fibrosis, Sarcoidosis",
author = "Patterson, {Karen C.} and Franek, {Beverly S.} and Joachim M{\"u}ller-Quernheim and Sperling, {Anne I.} and Sweiss, {Nadera J.} and Niewold, {Timothy B.}",
year = "2013",
month = "3",
doi = "10.1016/j.cyto.2012.12.016",
language = "English (US)",
volume = "61",
pages = "906--911",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Circulating cytokines in sarcoidosis

T2 - Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease

AU - Patterson, Karen C.

AU - Franek, Beverly S.

AU - Müller-Quernheim, Joachim

AU - Sperling, Anne I.

AU - Sweiss, Nadera J.

AU - Niewold, Timothy B.

PY - 2013/3

Y1 - 2013/3

N2 - Aims: Sarcoidosis is a granulomatous disease of unknown etiology marked by tremendous clinical heterogeneity. Many patients enter remission with good long-term outcomes. Yet, chronic disease is not uncommon, and this important phenotype remains understudied. Identified alterations in local and circulating cytokines-specifically targeted for study, and often in the acute phase of disease-have informed our growing understanding of the immunopathogenesis of sarcoidosis. Our aim was to evaluate a broad panel of circulating cytokines in patients with chronic sarcoidosis. Among those with chronic disease, pulmonary fibrosis occurs in only a subset. To gain more insight into the determinants of the fibrotic response, we also determined if the phenotypes of fibrotic and non-fibrotic pulmonary sarcoidosis have distinct cytokine profiles. Results: In patients with sarcoidosis compared to controls, IL-5 was decreased, and IL-7 was increased. Both of these comparisons withstood rigorous statistical correction for multiple comparisons. GM-CSF met a nominal level of significance. We also detected an effect of phenotype, where IL-5 was significantly decreased in non-fibrotic compared to fibrotic pulmonary sarcoidosis, and compared to controls. Compared to controls, there was a trend towards a significant increase in IL-7 in fibrotic, but not in non-fibrotic pulmonary sarcoidosis. In contrast, compared to controls, there was a trend towards a significant increase in GM-CSF in non-fibrotic, but not in fibrotic pulmonary sarcoidosis. Conclusions: In a comprehensive evaluation of circulating cytokines in sarcoidosis, we found IL-5, IL-7, and GM-CSF to be altered. These findings provide a window into the immunopathogenesis of sarcoidosis. IL-7 is a novel sarcoidosis cytokine and, as a master regulator of lymphocytes, is an attractive target for further studies. By observing an effect of phenotype upon cytokine patterns, we also identify specific immune alterations which may contribute to clinical heterogeneity.

AB - Aims: Sarcoidosis is a granulomatous disease of unknown etiology marked by tremendous clinical heterogeneity. Many patients enter remission with good long-term outcomes. Yet, chronic disease is not uncommon, and this important phenotype remains understudied. Identified alterations in local and circulating cytokines-specifically targeted for study, and often in the acute phase of disease-have informed our growing understanding of the immunopathogenesis of sarcoidosis. Our aim was to evaluate a broad panel of circulating cytokines in patients with chronic sarcoidosis. Among those with chronic disease, pulmonary fibrosis occurs in only a subset. To gain more insight into the determinants of the fibrotic response, we also determined if the phenotypes of fibrotic and non-fibrotic pulmonary sarcoidosis have distinct cytokine profiles. Results: In patients with sarcoidosis compared to controls, IL-5 was decreased, and IL-7 was increased. Both of these comparisons withstood rigorous statistical correction for multiple comparisons. GM-CSF met a nominal level of significance. We also detected an effect of phenotype, where IL-5 was significantly decreased in non-fibrotic compared to fibrotic pulmonary sarcoidosis, and compared to controls. Compared to controls, there was a trend towards a significant increase in IL-7 in fibrotic, but not in non-fibrotic pulmonary sarcoidosis. In contrast, compared to controls, there was a trend towards a significant increase in GM-CSF in non-fibrotic, but not in fibrotic pulmonary sarcoidosis. Conclusions: In a comprehensive evaluation of circulating cytokines in sarcoidosis, we found IL-5, IL-7, and GM-CSF to be altered. These findings provide a window into the immunopathogenesis of sarcoidosis. IL-7 is a novel sarcoidosis cytokine and, as a master regulator of lymphocytes, is an attractive target for further studies. By observing an effect of phenotype upon cytokine patterns, we also identify specific immune alterations which may contribute to clinical heterogeneity.

KW - Cytokines

KW - Interleukin-5

KW - Interleukin-7

KW - Pulmonary fibrosis

KW - Sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=84875379314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875379314&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2012.12.016

DO - 10.1016/j.cyto.2012.12.016

M3 - Article

C2 - 23384655

AN - SCOPUS:84875379314

VL - 61

SP - 906

EP - 911

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 3

ER -